Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.44 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.44 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.44 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.42 |
| ▸ | RAF1 | P04049 | 2/20 | 0.41 |
| ▸ | TLK2 | Q86UE8 | 4/20 | 0.40 |
| ▸ | GSK3B | P49841 | 2/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 3/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3572688 | 0.93 | FLT3 (0.41) | CDYL2CDYLCDY1; CDY1BNOX4RET | |
| SCHEMBL3581212 | 0.92 | NOX4 (0.46) | CDYL2CDYLCDY1; CDY1BNOX4RAF1 | |
| SCHEMBL4758177 | 0.91 | CDYL2 (0.44) | CDYL2CDYLCDY1; CDY1BNOX4RAF1 | |
| SCHEMBL3581378 | 0.91 | CDYL2 (0.44) | CDYL2CDYLCDY1; CDY1BNOX4RAF1 | |
| SCHEMBL3572331 | 0.88 | LMNA (0.45) | CDYL2CDYLCDY1; CDY1BRAF1TLK2 | |
| SCHEMBL3581209 | 0.88 | NOX4 (0.44) | CDYL2CDYLCDY1; CDY1BNOX4RAF1 | |
| SCHEMBL4758595 | 0.88 | NOX4 (0.54) | CDYL2CDYLCDY1; CDY1BNOX4TLK2 | |
| SCHEMBL4758589 | 0.88 | NOX4 (0.54) | CDYL2CDYLCDY1; CDY1BNOX4TLK2 | |
| SCHEMBL3572683 | 0.85 | FLT3 (0.43) | CDYL2CDYLCDY1; CDY1BNOX4RET | |
| SCHEMBL3572834 | 0.84 | CHEK1 (0.41) | NOX4RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7692005-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2010-04-06 | — | — | US | claimed |
| EP-1902025-A1 | KINASE INHIBITORS | Allergan, Inc. (US) | 2008-03-26 | — | — | EP | claimed |
| US-20070032478-A1 | Kinase Inhibitors | ALLERGAN, INC. | 2007-02-08 | — | — | US | claimed |
| WO-2007008895-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2007-01-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032478-A1 | Kinase Inhibitors | ABL1, LCK, ERBB2 | CDYL2 695/4885CDYL 746/4885CDY1; CDY1B 1618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.